Mitsubishi UFJ Trust & Banking
NKTR icon

Mitsubishi UFJ Trust & Banking’s Nektar Therapeutics NKTR Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$141K Buy
+2,023
New +$148K ﹤0.01% 1425
2021
Q3 		– Sell
-895
Closed -$238K – 1394
2021
Q2 		$238K Sell
895
-56
-6% -$15.5K ﹤0.01% 1238
2021
Q1 		$243K Buy
951
+204
+27% +$63.5K ﹤0.01% 1179
2020
Q4 		$190K Buy
747
+560
+299% +$145K ﹤0.01% 1254
2020
Q3 		$46K Buy
+187
New +$58.8K ﹤0.01% 1306
2020
Q1 		– Sell
-12
Closed -$4K – 1320
2019
Q4 		$4K Sell
12
-8,937
-100% -$2.59M ﹤0.01% 1318
2019
Q3 		$2.44M Sell
8,949
-382
-4% -$140K 0.01% 803
2019
Q2 		$4.98M Buy
9,331
+72
+0.8% +$36.1K 0.02% 662
2019
Q1 		$4.67M Buy
9,259
+36
+0.4% +$21.3K 0.02% 649
2018
Q4 		$4.55M Buy
9,223
+721
+8% +$435K 0.02% 634
2018
Q3 		$7.77M Sell
8,502
-13,191
-61% -$11.3M 0.03% 566
2018
Q2 		$15.9M Buy
+21,693
New +$25M 0.03% 605

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's NKTR Position: Q2 2026 in Review

Mitsubishi UFJ Trust & Banking opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 2,023 shares worth $141K. The stake represents ﹤0.01% of the portfolio and ranks #1425 among its holdings. This is a return to the name: Mitsubishi UFJ Trust & Banking previously reported a position in NKTR as recently as Q2 2021.

Mitsubishi UFJ Trust & Banking first reported a position in NKTR in Q2 2018 and has held it in 12 quarters since. The position peaked at $15.9M in Q2 2018. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Mitsubishi UFJ Trust & Banking held 2,023 shares of Nektar Therapeutics worth $141K as of Q2 2026.
  • Nektar Therapeutics was a new Mitsubishi UFJ Trust & Banking position in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of Mitsubishi UFJ Trust & Banking's portfolio in Q2 2026, its #1425 holding.
  • Mitsubishi UFJ Trust & Banking first reported a position in Nektar Therapeutics in Q2 2018 and has held it in 12 quarters since.
  • Mitsubishi UFJ Trust & Banking's Nektar Therapeutics position peaked at $15.9M in Q2 2018.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q2 2026, filed 6 Aug 2026.